Akebia’s Thrice-Weekly Vadadustat Meets Primary Endpoint in VOCAL Anemia Trial
Bitget2026/11/05 12:15- Akebia Therapeutics reported topline VOCAL trial results showing three-times-weekly vadadustat met its primary goal of non-inferiority to ESA treatment in maintaining hemoglobin.
- The trial enrolled 353 patients with kidney disease-related anemia receiving in-center hemodialysis; serious treatment-emergent adverse event rates were similar between treatments.
- The three-times-weekly regimen remains investigational. Vafseo, the drug’s brand name, is approved for once-daily use.
- FDA approval came in March 2024 for adults receiving dialysis for at least three months; US availability began in January 2025.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Crypto prices
More
